Setting the Pace with 

AVEIR™ Leadless Pacemakers

Single and Dual Chamber Leadless Pacemaker Solutions, only from Abbott

AVEIR Leadless Pacemakers


Discover the Leadless Advantage





For the first time ever, see how Single Chamber Atrial Leadless Pacing can help patients with:

  • Sinus node dysfunction and normal AV and intraventricular conduction systems

Explore Single Chamber Ventricular Leadless Pacing for patients with:

  • Significant bradycardia and normal sinus rhythm with only rare episodes of AV block or sinus arrest
  • Chronic atrial fibrillation

Redefine the patient experience using  Dual Chamber Leadless Pacing solutions for patients living with:

  • Sick sinus syndrome
  • Chronic, symptomatic second- and third-degree AV block
  • Symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out

Upgradeable System2

Patient therapy can be tailored by implanting an atrial or ventricular device alone, or both combined for dual chamber support. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later.

Treatment option 1: Start with the atrial device. 

Treat sinus node dysfunction today.

AVEIR AR in heart

Add a ventricular device for heart block later.

AVEIR DR in heart

i2i™ communication is enabled.

i2i symbol

Activate dual chamber pacing therapy DDD(R) via i2i communication.

AVEIR DR in heart

Treatment option 2: Start with the ventricular device. 

Treat rare intermittent heart block today.

AVEIR VR in heart

Add an atrial device for sick sinus syndrome later.

AVEIR DR in heart

i2i communication is enabled.

i2i symbol

Activate dual chamber pacing therapy DDD(R) via i2i communication.

AVEIR DR in heart

New Leadless Pacing Options2

With sensing and pacing in both the right atrium and right ventricle, you now have AAI(R), VVI(R), and DDD(R) leadless configurations to consider. You can match your patient's pacing needs today and then upgrade over time as those needs change.

Continuous AV, Beat-to-Beat Synchrony via Implant-to-Implant (i2i™) Technology2

To support dual chamber therapy, each implant communicates beat-to-beat with a paired, co-implanted device using i2i communication. This novel technology employs low energy, subthreshold pulses between implanted devices using the conductive nature of the body's blood pool and myocardial tissue. These high frequency pulses of data are delivered concurrently with each locally paced or sensed event, without impact on pacing or intrinsic sensing.

Long-Term Retrieval3

This allows for the replacement of the atrial or ventricular device at end of service (EOS) without leaving hardware behind.

Aveir DR Long Term Catheter

Specialty designed retrieval catheter supported by step-by-step protocol.

Aveir DR Long Term Catheter

Through nine years regardless of implant duration, AVEIR™ VR Leadless Pacemaker (LP) predicate device has a long-term retrieval success rate above 88%.3

Aveir DR's active fixation helix

Active fixation helix uses a screw-in mechanism to enable both implantation and long-term retrieval of the LP.

Mapping Prior to Fixation

AVEIR VR and AVEIR AR LPs can measure P/R-waves, impedance and Current of Injury via commanded EGM, and an initial capture threshold before fixation by simply touching the electrode to the endocardial tissue.The LPs are engaged with a rotational motion in the endocardium, and mapping capability is designed to help reduce the number of repositioning attempts.2


98% of patients had successful ventricular implants with 1 or less repositioning attempts.4


90% of patients had successful atrial implants with 1 or less repositioning attempts.4

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.


  1. AVEIR DR FDA approval.
  2. AVEIR Leadless Pacemakers and Delivery Catheter IFU. ARTEN600284235.
  3. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals: A Worldwide Nanostim Experience out of 9y. Presented at: APHRS 2022; Nov 18-20, 2022; Singapore.
  4. The New England Journal of Medicine (NEJM), May 2023,

MAT-2306873 v5.0